Hormone Therapy for Prostate Cancer Annapolis MD

Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found. The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

Edward Michael Zagula, MD
(410) 266-8049
600 Ridgely Ave Ste 130
Annapolis, MD
Specialties
Urology
Gender
Male
Education
Medical School: Wv Univ Sch Of Med, Morgantown Wv 26506
Graduation Year: 1979

Data Provided by:
Karen Elizabeth Boyle, MD
(443) 286-2721
2015 Compton Ct
Annapolis, MD
Specialties
Urology
Gender
Female
Education
Medical School: Albany Med Coll, Albany Ny 12208
Graduation Year: 1998

Data Provided by:
Eric J Schwartz, MD
(410) 266-8049
600 Ridgely Ave Ste 130
Annapolis, MD
Specialties
Urology
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
George Wei-Kung Yu, MD
(410) 897-0540
116 Defense Hwy Ste 200
Annapolis, MD
Specialties
Urology
Gender
Male
Education
Medical School: Tufts Univ Sch Of Med, Boston Ma 02111
Graduation Year: 1973

Data Provided by:
Ronald Charles Kretkowski, MD
(301) 699-3192
2973 Southaven Dr
Annapolis, MD
Specialties
Urology
Gender
Male
Education
Medical School: Umdnj-New Jersey Med Sch, Newark Nj 07103
Graduation Year: 1968

Data Provided by:
Barry Haydon Wells, MD
600 Ridgely Ave
Annapolis, MD
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Ks Sch Of Med, Kansas City Ks 66103
Graduation Year: 1983

Data Provided by:
John Eric Danneberger, MD
(410) 266-8049
600 Ridgely Ave Ste 130
Annapolis, MD
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Pittsburgh Sch Of Med, Pittsburgh Pa 15261
Graduation Year: 1982
Hospital
Hospital: North Arundel Hospital, Glen Burnie, Md; Anne Arundel Med Ctr, Annapolis, Md
Group Practice: Anne Arundel Urology

Data Provided by:
David William Mc Dermott, MD
(410) 266-8049
600 Ridgely Ave Ste 130
Annapolis, MD
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Tx Med Sch At San Antonio, San Antonio Tx 78284
Graduation Year: 1977

Data Provided by:
Raymond George Herzinger, MD
(410) 266-8049
600 Ridgely Ave Ste 130
Annapolis, MD
Specialties
Urology
Gender
Male
Education
Medical School: George Washington Univ Sch Of Med & Hlth Sci, Washington Dc 20037
Graduation Year: 1965

Data Provided by:
Steven Douglas Rock, MD
(410) 266-8049
1193 Bunker Ave
Arnold, MD
Specialties
Urology
Gender
Male
Education
Medical School: Suny At Buffalo Sch Of Med & Biomedical Sci, Buffalo Ny 14214
Graduation Year: 1991

Data Provided by:
Data Provided by:

Hormone Therapy for Prostate Cancer

Provided By:

TUESDAY, Sept. 22 (HealthDay News) -- Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found.

The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

The study findings were scheduled to be presented Tuesday at the European Cancer Organization meeting in Berlin.

In a news release from the European Cancer Organization, the researchers described the types of hormone therapy used: removal of the testicles to eliminate the main source of testosterone production; injections of gonadotropin-releasing hormone agonists to reduce testosterone production by the testicles; and anti-androgen pills that block testosterone from attaching to prostate cells. Most of the patients received one treatment, but 38 percent were given two types of drugs, the study authors noted.

The men were followed for an average of three years and monitored for ischemic heart disease, heart attacks, arrhythmia, and heart failure.

"We found that prostate cancer patients treated with hormone therapy had an elevated risk of developing all of the individual types of heart problems and that they were more likely than normal to die from those causes," study lead author Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London, England, said in the news release.

Specifically, hormone therapy was associated with a 24 percent increased risk of heart attack, a 19 percent increased risk of arrhythmia, a 31 percent increased risk of ischemic heart disease, and a 26 percent increased risk of heart failure, the researchers found. The increased risk of heart disease began a few months after the men began hormone therapy.

The study also found that hormone therapy was associated with a 28 percent increased risk of fatal heart attack, a 21 percent increased risk of dying from heart disease, a 26 percent increased risk of death from heart failure, and a 5 percent increased risk of fatal arrhythmia.

"In a more detailed analysis by type of hormone therapy, the lowest increase in risk for ischemic heart disease, heart attack and heart failure was seen in the group taking anti-androgen therapy, and we saw no increase in risk of death from heart disease in this group. Patients on gonadotropin-releasing hormone agonist therapy had the highest risk of these problems," Van Hemelrijck said.

The findings suggest that physicians should consider heart-related side effects when prescribing hormone therapy for prostate cancer patients and may want to refer patients to a cardiologist before the start of hormone therapy, the researchers stated.

More information

The American Urological Association Foundation has more about hormone therapy for prostate cancer.

SOURCE: European Cancer Organization, news release, Sept. 22, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com